Havila Kystruten AS reports a solid operational performance for Q4 2024 and January 2025, reflecting steady demand and continued improvements in key revenue metrics.Occupancy for Q4 2024 reached 78%, ...
Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call and ...
MNOK 51.7. The objectives of the combined company, Zelluna ASA, will be as follows: Advance the world's first MAGE-A4 targeting TCR-NK program, ZI-MA4-1, into first-in-human clinical studies ...
of the issuance of 19,873,071 shares at a subscription price of NOK 2.60 per share, raising gross proceeds of approx. MNOK 51.7. * The objectives of the combined company, Zelluna ASA, will be as ...
MNOK 51.7. The objectives of the combined company, Zelluna ASA, will be as follows: Advance the world’s first MAGE-A4 targeting TCR-NK program, ZI-MA4-1, into first-in-human clinical studies treating ...
The business to be transferred represented revenues of approx. MNOK 600 in 2023. Directors," says Thomas Borgen, Chairman of Kongsberg Digital. “The combined digital capabilities of KM and KDI, along ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback